STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3523 by analyst upside · 2026-06-27
LLY
Eli Lilly and Company
Healthcare · Market Cap $1.08T · P/E 42.9x
ANALYST PRICE TARGET
+1.2%
implied upside to consensus target
Current Price $1208.12
Consensus Target $1222.62
Bull Target $1500.0
Bear Target $850.0
Analysts Covering 29
ANALYST CONSENSUS — BUY
Strong Buy
6
Buy
17
Hold
6
Sell
0
52-Week Low $623.78
52-Week High $1215.57
YTD Return +12.2%
FUNDAMENTALS
Market Cap $1.08T
P/E Ratio (TTM) 42.9x
Forward P/E 27.2x
EPS (TTM) $28.19
PEG Ratio 1.50
Dividend Yield 0.61%
Revenue (TTM) $72.2B
Profit Margin 35.0%
52-WEEK RANGE
52-Week Low $623.78
52-Week High $1215.57
Current Price $1208.12
Bear Target $850.0
Bull Target $1500.0
● Now $1208.12 ● Target $1222.62
TRADING DATA
Avg Volume 3.2M
YTD Return +12.2%
Analyst Count 29
Consensus Buy
Upside to Target +1.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Eli Lilly and Company (LLY) is currently trading at $1208.12 with a Wall Street consensus price target of $1222.62, implying potential upside of 1.2% over the next 12 months. 29 analysts currently cover LLY, with a consensus rating of Buy — 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1500.0, while the most cautious has a target of $850.0.

LLY operates in the Healthcare sector with a market capitalisation of $1.08T. The stock is up 12.2% year-to-date and is currently trading near the upper end of its 52-week range of $623.78 – $1215.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LLY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies — Reiterated
Buy → Buy 2026-06-09 50% win rate (6 calls)
B of A Securities — Reiterated
Buy → Buy 2026-05-26 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-05-05 Building track record
Guggenheim reit
Buy → Buy 2026-05-05 62% win rate (8 calls)
Wolfe Research reit
Outperform → Outperform 2026-05-04 Building track record
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-05-01 40% win rate (10 calls)
Guggenheim — Reiterated
Buy → Buy 2026-04-22 62% win rate (8 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-04-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →